Search

Your search keyword '"Spadaro, Pietro"' showing total 18 results
Start Over Author "Spadaro, Pietro"
18 results on '"Spadaro, Pietro"'

1. Management of radiation-induced oral mucositis in head and neck cancer patients: a real-life survey among 25 Italian radiation oncology centers

Author

Bergamaschi, Luca, Vincini, Maria Giulia, Zaffaroni, Mattia, Pepa, Matteo, Angelicone, Ilaria, Astone, Antonio, Bergamini, Cristiana, Buonopane, Sergio, Conte, Mario, De Rosa, Nicola, Deantoni, Chiara, Dell’Oca, Italo, Di Gennaro, Davide, Di Muzio, Nadia, Osti, Mattia Falchetto, Federico, Manuela, Ferini, Gianluca, Franzese, Ciro, Gatti, Marco, Grillo, Antonietta, Iorio, Vincenzo, Manzo, Roberto, Marmiroli, Luca, Martin, Giuseppe, Mazzuca, Federica, Molinaro, Maria Angela, Muto, Matteo, Pacelli, Roberto, Pepe, Alfonsina, Perillo, Annarita, Russo, Donatella, Salerno, Francesca, Spadaro, Pietro, Viola, Anna, Iorio, Giuseppe Carlo, Muto, Paolo, Ricardi, Umberto, and Alterio, Daniela

Published
2024
Full Text
View/download PDF

2. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib

Author

Tiseo, Marcello, Ippolito, Massimo, Scarlattei, Maura, Spadaro, Pietro, Cosentino, Sebastiano, Latteri, Fiorenza, Ruffini, Livia, Bartolotti, Marco, Bortesi, Beatrice, Fumarola, Claudia, Caffarra, Cristina, Cavazzoni, Andrea, Alfieri, Roberta R., Petronini, Pier Giorgio, Bordonaro, Roberto, Bruzzi, Paolo, Ardizzoni, Andrea, and Soto Parra, Hector J.

Published
2014
Full Text
View/download PDF

5. TAM895755_Supplementary_material_CLN – Supplemental material for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

Author

Adamo, Vincenzo, Ricciardi, Giuseppina Rosaria Rita, Giuffrida, Dario, Scandurra, Giuseppa, Russo, Antonio, Blasi, Livio, Spadaro, Pietro, Iacono, Carmelo, Parra, Hector J. Soto, Savarino, Antonino, Ferraú, Francesco, Zerilli, Filippo, Verderame, Francesco, Butera, Alfredo, Santangelo, Carlo, Franchina, Veronica, and Caruso, Michele

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, TAM895755_Supplementary_material_CLN for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study by Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio Blasi, Pietro Spadaro, Carmelo Iacono, Hector J. Soto Parra, Antonino Savarino, Francesco Ferraú, Filippo Zerilli, Francesco Verderame, Alfredo Butera, Carlo Santangelo, Veronica Franchina and Michele Caruso in Therapeutic Advances in Medical Oncology

Published
2019
Full Text
View/download PDF

6. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

Author

Adamo, Vincenzo, primary, Ricciardi, Giuseppina Rosaria Rita, additional, Giuffrida, Dario, additional, Scandurra, Giuseppa, additional, Russo, Antonio, additional, Blasi, Livio, additional, Spadaro, Pietro, additional, Iacono, Carmelo, additional, Soto Parra, Hector J., additional, Savarino, Antonino, additional, Ferraú, Francesco, additional, Zerilli, Filippo, additional, Verderame, Francesco, additional, Butera, Alfredo, additional, Santangelo, Carlo, additional, Franchina, Veronica, additional, and Caruso, Michele, additional

Published
2019
Full Text
View/download PDF

7. Multicenter study of the evaluation of eribulin (E) use in Sicily in metastatic breast cancer (MBC): A prospective registry (VESPRY trial).

Author

Adamo, Vincenzo, primary, Ricciardi, Giuseppina, additional, Giuffrida, Dario, additional, Scandurra, Giuseppa, additional, Russo, Antonio, additional, Blasi, Livio, additional, Spadaro, Pietro, additional, Lucenti, Antonio, additional, Soto Parra, Hector J., additional, Savarino, Antonino, additional, Ferraú, Francesco, additional, Zerilli, Filippo, additional, Verderame, Francesco, additional, Butera, Alfredo, additional, Franchina, Veronica, additional, Cottini, Lorenzo, additional, Fedele, Guido, additional, and Caruso, Michele, additional

Published
2017
Full Text
View/download PDF

8. Multi-istitutional study of the evaluation of eribulin (E) use in Sicily in metastatic breast cancer (MBC): A prospective registry (VESPRY trial).

Author

Adamo, Vincenzo, primary, Ricciardi, Giuseppina Rosaria Rita, additional, Franchina, Veronica, additional, Ferraro, Giuseppa, additional, Caruso, Michele, additional, Bronte, Giuseppe, additional, Banna, Giuseppe Luigi, additional, Spadaro, Pietro, additional, Savarino, Antonino, additional, Iacono, Carmelo, additional, Soto Parra, Hector J., additional, Spada, Massimiliano, additional, Safina, Valentina, additional, Blasi, Livio, additional, Zerilli, Filippo, additional, Prestifilippo, Angela, additional, Giannitto-Giorgio, Carmelo, additional, Alberio, Davide, additional, Cottini, Lorenzo, additional, and Russo, Antonio, additional

Published
2015
Full Text
View/download PDF

9. Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study

Author

Napolitano, Mariasanta, primary, Saccullo, Giorgia, additional, Malato, Alessandra, additional, Sprini, Delia, additional, Ageno, Walter, additional, Imberti, Davide, additional, Mascheroni, Doris, additional, Bucherini, Eugenio, additional, Gallucci, Pina, additional, D'Alessio, Andrea, additional, Prantera, Tullia, additional, Spadaro, Pietro, additional, Rotondo, Stefano, additional, Di Micco, Pierpaolo, additional, Oriana, Vincenzo, additional, Urbano, Oreste, additional, Recchia, Francesco, additional, Ghirarduzzi, Angelo, additional, Lo Coco, Lucio, additional, Mancuso, Salvatrice, additional, Casuccio, Alessandra, additional, Rini, Giovam Battista, additional, and Siragusa, Sergio, additional

Published
2014
Full Text
View/download PDF

10. Role of trastuzumab in infracentimetric HER2-positive breast cancer: The southern Italy experience.

Author

Adamo, Vincenzo, primary, Ricciardi, Giuseppina R. R., additional, Adamo, Barbara, additional, Caruso, Michele, additional, Soto Parra, Hector J., additional, Iacono, Carmelo, additional, Prestifilippo, Angela, additional, Russo, Antonio, additional, Gebbia, Vittorio, additional, Borsellino, Nicolo, additional, Blasi, Livio, additional, Lavenia, Giuseppe, additional, Spadaro, Pietro, additional, Verderame, Francesco, additional, and Tuccari, Giovanni, additional

Published
2014
Full Text
View/download PDF

11. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib

Author

Tiseo, Marcello, primary, Ippolito, Massimo, additional, Scarlattei, Maura, additional, Spadaro, Pietro, additional, Cosentino, Sebastiano, additional, Latteri, Fiorenza, additional, Ruffini, Livia, additional, Bartolotti, Marco, additional, Bortesi, Beatrice, additional, Fumarola, Claudia, additional, Caffarra, Cristina, additional, Cavazzoni, Andrea, additional, Alfieri, Roberta R., additional, Petronini, Pier Giorgio, additional, Bordonaro, Roberto, additional, Bruzzi, Paolo, additional, Ardizzoni, Andrea, additional, and Soto Parra, Hector J., additional

Published
2013
Full Text
View/download PDF

12. The Optimal Duration of Anticoagulant Therapy In Patients with Cancer-Related Deep Vein Thrombosis: The Advantage of Using Residual Vein Thrombosis (the Cancer-DACUS Study)

Author

Siragusa, Sergio, primary, Malato, Alessandra, additional, Mascheroni, Doris, additional, Ageno, Walter, additional, Bucherini, Eugenio, additional, Spadaro, Pietro, additional, Imberti, Davide, additional, Saccullo, Giorgia, additional, Coco, Lucio Lo, additional, Rotondo, Stefano, additional, Santoro, Rita, additional, Micco, Pierpaolo Di, additional, Oriana, Vincenzo, additional, Urbano, Oreste, additional, Prantera, Tullio, additional, Recchia, Francesco, additional, D'Alessio, Andrea, additional, Gallucci, Pina, additional, Ghirarduzzi, Angelo, additional, Cormaci, Oreste, additional, Caracciolo, Clementina, additional, and Abbadessa, Vincenzo, additional

Published
2010
Full Text
View/download PDF

13. Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases

Author

Pergolizzi, Stefano, primary, Adamo, Vincenzo, additional, Russi, Elvio, additional, Santacaterina, Anna, additional, Maisano, Roberto, additional, Numico, Gianmauro, additional, Palazzolo, Carmela, additional, Ferraù, Francesco, additional, Settineri, Nicola, additional, Altavilla, Giuseppe, additional, Girlando, Andrea, additional, Spadaro, Pietro, additional, and Cascinu, Stefano, additional

Published
2006
Full Text
View/download PDF

15. Combined Epirubicin and Interleukin-2 Regimen in the Treatment of Malignant Mesothelioma: A Multicenter Phase II Study of the Italian Group on Rare Tumors

Author

Bretti, Sergio, primary, Berruti, Alfredo, additional, Dogliotti, Luigi, additional, Castagneto, Bruno, additional, Bertulli, Rossella, additional, Spadaro, Pietro, additional, Toscano, Giuseppe, additional, Astorre, Paolo, additional, Verusio, Claudio, additional, Lionetto, Rita, additional, Bruzzi, Paolo, additional, and Santoro, Armando, additional

Published
1998
Full Text
View/download PDF

16. Multi-istitutional study of the evaluation of eribulin (E) use in Sicily in metastatic breast cancer (MBC): A prospective registry (VESPRY trial)

Author

Adamo, Vincenzo, Ricciardi, Giuseppina Rosaria Rita, Franchina, Veronica, Ferraro, Giuseppa, Caruso, Michele, Bronte, Giuseppe, Banna, Giuseppe Luigi, Spadaro, Pietro, Savarino, Antonino, Iacono, Carmelo, HECTOR SOTO PARRA, Spada, Massimiliano, Safina, Valentina, Blasi, Livio, Zerilli, Filippo, Prestifilippo, Angela, Giannitto-Giorgio, Carmelo, Alberio, Davide, Cottini, Lorenzo, and Russo, Antonio

Subjects
Cancer Research, Oncology

17. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib

Author

Roberto Bordonaro, Pier Giorgio Petronini, Cristina Caffarra, Marcello Tiseo, P. Spadaro, Massimo Ippolito, Paolo Bruzzi, F. Latteri, Maura Scarlattei, Roberta Alfieri, Marco Bartolotti, Beatrice Bortesi, Claudia Fumarola, Andrea Ardizzoni, Sebastiano Cosentino, Hector Soto Parra, Andrea Cavazzoni, Livia Ruffini, Tiseo, Marcello, Ippolito, Massimo, Scarlattei, Maura, Spadaro, Pietro, Cosentino, Sebastiano, Latteri, Fiorenza, Ruffini, Livia, Bartolotti, Marco, Bortesi, Beatrice, Fumarola, Claudia, Caffarra, Cristina, Cavazzoni, Andrea, Alfieri, Roberta R., Petronini, Pier Giorgio, Bordonaro, Roberto, Bruzzi, Paolo, Ardizzoni, Andrea, and Soto Parra, Hector J.

Subjects
Oncology, Male, Cancer Research, 18FDG-PET, Lung Neoplasms, Toxicology, NSCLC, Carcinoma, Non-Small-Cell Lung, Medicine, Pharmacology (medical), Non-Small-Cell Lung, education.field_of_study, Middle Aged, Prognosis, Response assessment, Treatment Outcome, Erlotinib, Disease Progression, Radiopharmaceutical, Female, Non small cell, Metabolic response, Adult, Aged, Disease-Free Survival, Erlotinib Hydrochloride, Humans, Neoplasm Staging, Positron-Emission Tomography, Protein Kinase Inhibitors, Quinazolines, Radiopharmaceuticals, Fluorodeoxyglucose F18, Human, medicine.drug, medicine.medical_specialty, Prognosi, Population, Protein Kinase Inhibitor, Progressive Metabolic Disease, Internal medicine, 18fdg pet, Lung cancer, education, neoplasms, Pharmacology, Fluorodeoxyglucose, business.industry, Carcinoma, Quinazoline, medicine.disease, respiratory tract diseases, Lung Neoplasm, business
Abstract

Background: [18F]fluorodeoxyglucose (FDG)-PET is being evaluated as a tool for the early detection of response to various targeted agents in solid tumors. The aim of this study was to evaluate the predictive value of PET response after 2 days of erlotinib in unselected pretrated patients with stage IV NSCLC. Patients and methods: FDG-PET/CT scans were conducted at baseline and after 2 days of erlotinib, with a CT evaluation performed at baseline and after 45-60 days of therapy. PET responses were evaluated by quantitative changes on SUVmax tumor/non-tumor ratio and classified according to EORTC criteria. PET responses were compared with RECIST responses and related to progression-free (PFS) and overall (OS) survival. Erlotinib effects on glucose uptake were also studied in a panel of NSCLC cell lines. Results: Fifty-three patients were enrolled. At 2 days of erlotinib, 20 (38 %) patients showed partial metabolic response (PMR), 25 (47 %) had stable metabolic disease (SMD) and 8 (15 %) had progressive metabolic disease (PMD). All patients with PMD had confirmed RECIST progression at 45-60 days. Patients with early PMR and SMD had significantly longer PFS (p < 0.001 and p = 0.001, respectively) and OS (p = 0.001 for both) than PMD patients. Conclusions: FDG-PET assessment after 2 days of erlotinib could be useful to identify early resistent patients and to predict survival in unselected NSCLC pretreated population. © 2013 Springer-Verlag.

Published
2014

18. Management of radiation-induced oral mucositis in head and neck cancer patients: a real-life survey among 25 Italian radiation oncology centers.

Author

Bergamaschi L, Vincini MG, Zaffaroni M, Pepa M, Angelicone I, Astone A, Bergamini C, Buonopane S, Conte M, De Rosa N, Deantoni C, Dell'Oca I, Di Gennaro D, Di Muzio N, Osti MF, Federico M, Ferini G, Franzese C, Gatti M, Grillo A, Iorio V, Manzo R, Marmiroli L, Martin G, Mazzuca F, Molinaro MA, Muto M, Pacelli R, Pepe A, Perillo A, Russo D, Salerno F, Spadaro P, Viola A, Iorio GC, Muto P, Ricardi U, and Alterio D

Subjects
Humans, Mouthwashes therapeutic use, Sodium Bicarbonate therapeutic use, Hyaluronic Acid therapeutic use, Steroids, Mucositis drug therapy, Radiation Oncology, Stomatitis etiology, Stomatitis prevention & control, Radiation Injuries etiology, Radiation Injuries prevention & control, Head and Neck Neoplasms radiotherapy, Head and Neck Neoplasms drug therapy
Abstract

Aim: Radiation-induced oral mucositis (RIOM) is the most frequent side effect in head and neck cancer (HNC) patients treated with curative radiotherapy (RT). A standardized strategy for preventing and treating RIOM has not been defined. Aim of this study was to perform a real-life survey on RIOM management among Italian RT centers., Methods: A 40-question survey was administered to 25 radiation oncologists working in 25 different RT centers across Italy., Results: A total of 1554 HNC patients have been treated in the participating centers in 2021, the majority (median across the centers 91%) with curative intent. Median treatment time was 41 days, with a mean percentage of interruption due to toxicity of 14.5%. Eighty percent of responders provide written oral cavity hygiene recommendations. Regarding RIOM prevention, sodium bicarbonate mouthwashes, oral mucosa barrier agents, and hyaluronic acid-based mouthwashes were the most frequent topic agents used. Regarding RIOM treatment, 14 (56%) centers relied on literature evidence, while internal guidelines were available in 13 centers (44%). Grade (G)1 mucositis is mostly treated with sodium bicarbonate mouthwashes, oral mucosa barrier agents, and steroids, while hyaluronic acid-based agents, local anesthetics, and benzydamine were the most used in mucositis G2/G3. Steroids, painkillers, and anti-inflammatory drugs were the most frequent systemic agents used independently from the RIOM severity., Conclusion: Great variety of strategies exist among Italian centers in RIOM management for HNC patients. Whether different strategies could impact patients' compliance and overall treatment time of the radiation course is still unclear and needs further investigation., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results